1437 related articles for article (PubMed ID: 32918178)
1. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women.
Nayyar A; Strassle PD; Iles K; Jameison D; Jadi J; McGuire KP; Gallagher KK
Ann Surg Oncol; 2020 Nov; 27(12):4853-4860. PubMed ID: 32918178
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Park C; Heo JH; Mehta S; Han S; Spencer JC
Clin Drug Investig; 2023 Mar; 43(3):167-176. PubMed ID: 36740664
[TBL] [Abstract][Full Text] [Related]
3. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Hind D; Wyld L; Beverley CB; Reed MW
Cochrane Database Syst Rev; 2006 Jan; (1):CD004272. PubMed ID: 16437480
[TBL] [Abstract][Full Text] [Related]
4. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
Yuan C; Xie Z; Bian J; Huo J; Daily K
Breast Cancer Res Treat; 2020 Apr; 180(3):819-827. PubMed ID: 32172303
[TBL] [Abstract][Full Text] [Related]
6. Mortality impact of less-than-standard therapy in older breast cancer patients.
Yood MU; Owusu C; Buist DS; Geiger AM; Field TS; Thwin SS; Lash TL; Prout MN; Wei F; Quinn VP; Frost FJ; Silliman RA
J Am Coll Surg; 2008 Jan; 206(1):66-75. PubMed ID: 18155570
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
9. Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Locker GY; Sainsbury JR; Cuzick J;
Cancer; 2004 Aug; 101(4):735-40. PubMed ID: 15305403
[TBL] [Abstract][Full Text] [Related]
10. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Buzdar AU
Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
[TBL] [Abstract][Full Text] [Related]
11. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data.
Ali AA; Tawk R; Xiao H; Campbell E; Semykina A; Montero AJ; Mogos M; Diaby V
Cancer Med; 2019 Jan; 8(1):117-127. PubMed ID: 30548840
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
15. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
16. Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.
Mamguem Kamga A; Billa O; Ladoire S; Poillot ML; Jolimoy G; Roignot P; Coutant C; Desmoulins I; Maynadie M; Dabakuyo-Yonli TS
Breast; 2021 Oct; 59():79-86. PubMed ID: 34174766
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Park C; Park SK; Woo A; Ng BP
Qual Life Res; 2022 May; 31(5):1345-1357. PubMed ID: 35064415
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
